Be the first to like this
Ventrus Biosciences announced that S.L.A. Pharma has completed enrollment and randomization in the first pivotal Phase III study with diltiazem (VEN 307) for the treatment of anal fissures. VTUS has licensed the North American rights to diltiazem from S.L.A. Pharma and stated that initial top-line data from the study is expected to be available in May 2012. Importantly, the company also noted that trial enrollment occurred faster than initially expected.